Minerva Neurosciences, Inc (NERV) Given Average Recommendation of “Hold” by Analysts
Minerva Neurosciences, Inc (NASDAQ:NERV) has received an average recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $16.00.
A number of brokerages have issued reports on NERV. BidaskClub cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Zacks Investment Research cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Citigroup Inc. began coverage on shares of Minerva Neurosciences in a report on Friday, September 1st. They issued a “buy” rating and a $11.00 target price on the stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers lifted its holdings in Minerva Neurosciences by 35.9% in the second quarter. Rhumbline Advisers now owns 27,082 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 7,150 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Minerva Neurosciences in the second quarter worth about $159,000. EcoR1 Capital LLC bought a new position in Minerva Neurosciences in the second quarter worth about $1,981,000. Laurion Capital Management LP bought a new position in Minerva Neurosciences in the second quarter worth about $326,000. Finally, Vanguard Group Inc. lifted its holdings in Minerva Neurosciences by 13.4% in the first quarter. Vanguard Group Inc. now owns 939,297 shares of the biopharmaceutical company’s stock worth $7,608,000 after acquiring an additional 110,876 shares during the last quarter. 69.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Minerva Neurosciences (NERV) opened at 7.45 on Friday. The stock has a 50 day moving average price of $7.26 and a 200 day moving average price of $7.62. The stock’s market capitalization is $316.69 million. Minerva Neurosciences has a 12-month low of $5.55 and a 12-month high of $14.15.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.07. During the same quarter in the prior year, the firm posted ($0.18) earnings per share. On average, equities analysts anticipate that Minerva Neurosciences will post ($0.90) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/21/minerva-neurosciences-inc-nerv-given-average-recommendation-of-hold-by-analysts.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.